In this randomized, noninferiority trial among patients seeking emergency contraception after at least one episode of unprotected intercourse within five days of presentation, the levonorgestrel 52-mg intrauterine device (IUD) was noninferior to the copper T30A IUD at preventing pregnancy one month after IUD insertion. Adverse events between the two groups were similar.
Twirla, a new low-dose contraceptive patch, is effective at preventing pregnancy among American women, according to researchers. Phase III clinical trial results were favorable for efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system. The new patch uses a progestin and contains less estrogen than prior patches.
Hospitals are scrambling to ensure a smooth and effective process for vaccinating frontline healthcare workers against COVID-19. Leaders need to quickly equip their personnel with enough information to persuade them that the vaccine is safe and effective.
In this single-arm, open-label, Phase III study of a novel vaginal pH regulator gel among 1,384 sexually active women aged 18 to 35 years, the seven-cycle cumulative pregnancy rate was 13.7% (95% confidence interval, 10.0% to 17.5%).
Although questions and caveats remain, preliminary reports of two new COVID-19 vaccines in the 90% to 95% effectiveness range have bolstered hopes that healthcare workers may soon be protected and potentially large portions of the public immunized in 2021.
With the first vaccine for SARS-CoV-2 on the horizon and targeted for healthcare workers, there are safety concerns and trust issues that threaten to undermine immunization. However, all new vaccines are followed closely for adverse effects, and the oversight of COVID-19 immunization will include multiple systems of passive and active surveillance.